[8] CabanillasME, HuMI, : totreatornottotreat-andwithwhichdrug-thosearethequestions[J].JClinEndocrinolMetab,2014, 99: 4390-4396.
[9] KrajewskaJ, KukulskaA, [J].ExpOpinPharmacotherapy,2016,17（12）:1683-1691.
[10] SchlumbergerM, TaharaM, WirthL, -refractorythyroidcancer[J].NEJM,2015,372（7）: 621-630.
[11] SchlumbergerM, JarzabB, CabanillasME, （E7080）inAdvancedMedullaryThyroidCancer[J].ClinCancerRes, 2016, 22（1）:44-53.
[12] : AReviewinRefractoryThyroidCancer[J].TargetedOncology, 11（1）:115-122.
[13] FerrariS, PolittiU, SpisniR, [J].ExpRevAnticancerTherapy, 2015,15（8）: 863-874.
[14] BroseM, NuttingC , JarzabB, -refractory, locallyadvancedormetastaticdifferentiatedthyroidcancer:arandomised, double-blind, phase3trial[J].Lancet, 2014,384（9940）:319-328.
[15] ItoY, OnodaN, ItoK, [J].Thyroid,2017, 27（9）:1142-1148.
[16] SavvidesP, NagaiahG, LavertuP, [J].Thyroid, 2013, 23（5）:600-604.
[17] AhmedM, BarbachanoY, RiddellA, :aphaseⅡ studyinaUKbasedpopulation[J].EurJEndocrinol,2011, 165（2）:315-322.
[18] LamET, RingelMD, KloosRT, [J].JClinOncol,2010, 28（14）:2323-2330.
[19] ThomasL, LaiSY, DongW, : asystematicreview[J].Oncologist,2014, 19（3）:251-258.
[20] KarrasS, AnagnostisP, :anupdate[J].ExpOpinDrugMetabolToxicol,2014,10（3）:469-481.
[21] WellsS, RobinsonBO, GagelR, : arandomized, double-blindphaseⅢtrial[J].JClinOncol,2012,30（2）:134-141.
[22] LeboulleuxS, BastholtL, KrauseT, : arandomised, double-blind, phase2trial[J].LancetOncol,2012, 13（9）:897-905.
